Clinical Trial Update: Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating higher-dose TA-650, a form of infliximab, in rheumatoid arthritis examined efficacy and safety with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• TA-650 (Infliximab) (Infliximab)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2013-05-20